JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Henry Schein (NASDAQ:HSIC) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage currently has a $77.00 target price on the stock, down from their previous target price of $79.00.
Several other research firms have also recently weighed in on HSIC. Zacks Investment Research cut shares of Henry Schein from a hold rating to a sell rating in a report on Monday, November 13th. Robert W. Baird set a $95.00 price target on shares of Henry Schein and gave the stock a buy rating in a report on Thursday, October 19th. Stifel Nicolaus decreased their price target on shares of Henry Schein from $89.00 to $77.00 and set a hold rating on the stock in a report on Tuesday, November 7th. Craig Hallum raised shares of Henry Schein from a hold rating to a buy rating in a report on Tuesday, November 7th. Finally, Evercore ISI initiated coverage on shares of Henry Schein in a report on Thursday, January 4th. They issued an outperform rating and a $81.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of $83.71.
Henry Schein (NASDAQ HSIC) opened at $69.52 on Thursday. The firm has a market cap of $10,911.44, a price-to-earnings ratio of 20.03, a PEG ratio of 1.79 and a beta of 1.00. Henry Schein has a 1-year low of $63.01 and a 1-year high of $93.50. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86.
A number of large investors have recently made changes to their positions in HSIC. Toronto Dominion Bank grew its position in Henry Schein by 25.7% in the second quarter. Toronto Dominion Bank now owns 26,872 shares of the company’s stock worth $4,917,000 after acquiring an additional 5,487 shares in the last quarter. Gs Investments Inc. purchased a new position in Henry Schein in the second quarter worth $884,000. Wealth Enhancement Advisory Services LLC grew its position in Henry Schein by 100.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 10,091 shares of the company’s stock worth $817,000 after acquiring an additional 5,051 shares in the last quarter. Shell Asset Management Co. boosted its position in Henry Schein by 178.0% during the third quarter. Shell Asset Management Co. now owns 112,948 shares of the company’s stock valued at $13,155,000 after buying an additional 72,325 shares during the period. Finally, Quantitative Systematic Strategies LLC boosted its position in Henry Schein by 524.8% during the third quarter. Quantitative Systematic Strategies LLC now owns 14,658 shares of the company’s stock valued at $1,202,000 after buying an additional 12,312 shares during the period. Institutional investors own 91.15% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.